8-K 1 d733073d8k.htm 8-K 8-K





Washington, D.C. 20549







Pursuant to Rule 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 30, 2019



Zymeworks Inc.

(Exact name of registrant as specified in its charter)




British Columbia, Canada   001-38068   47-2569713

(State or other jurisdiction

of incorporation)

File Number)

(IRS Employer

Identification No.)

Suite 540, 1385 West 8th Avenue, Vancouver, British Columbia, Canada   V6H 3V9
(Address of principal executive offices)   (Zip Code)

(604) 678-1388

(Registrant’s telephone number, including area code)

Not Applicable

(Former name of former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒




ITEM 8.01


The following information is filed pursuant to Item 8.01, “Other Events.”

On April 30, 2019, Zymeworks Inc. (“Zymeworks”) issued a press release reporting that it has expanded its leadership team with the hiring of three new vice presidents to support its expanded global clinical development: Mark Hollywood, Senior Vice President, Technical and Manufacturing Operations; Neil Josephson, M.D., Vice President, Clinical Research; and Bruce Hart, Ph.D., Vice President, Regulatory Affairs. Zymeworks has also promoted David Poon, Ph.D., to Vice President, Business Development and Alliance Management. A copy of this press release is filed as exhibit 99.1 hereto.


ITEM 9.01


(d) Exhibits


Exhibit No.



99.1    Press Release issued by Zymeworks Inc. on April 30, 2019


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.





Date: April 30, 2019     By:   /s/ Neil Klompas
    Name:   Neil Klompas
    Title:   Chief Financial Officer